

**CARDIAC INSIGHT, INC.'S CARDEA SOLO™ WINS “TECH BREAKTHROUGH AWARD” FOR
“BEST WEARABLE SENSOR SOLUTION”**

KIRKLAND, WA. (June 7, 2018) – Cardiac Insight, Inc., continues to win industry accolades for its ground-breaking approach to wearable medical devices, software systems and proprietary algorithms. The company announced today that one of its featured cardiac products, Cardea SOLO™ has been awarded “Best Wearable Sensor Solution” in the MedTech category of the **2018 Tech Breakthrough Awards**. Cardiac Insight surpassed 3,000 other medtech submissions.

“Cardiac Insight is honored to receive recognition for Cardea SOLO, a game-changing technology improving the diagnosis and treatment of atrial fibrillation (AFib), and other abnormal heart rhythms,” said Brad Harlow, CEO of Cardiac Insight, Inc. “Our company is on the forefront of placing new tools in the hands of physicians to not only help identify silent killers and save lives, but also improve the work flow and productivity of healthcare providers.”

According to the award website, the mission of the Tech Breakthrough Awards is to honor excellence and recognize the creativity, hard work and success of technology companies, platforms, people and products. Nominations are judged by an independent panel of judges comprised of experts with hands-on relevant professional experience; senior-level, experienced technology executives, journalists and analysts. Criteria includes, but is not limited to:

- Engineering quality and innovation;
- Overall design and aesthetic, including hardware design where applicable, or UI/UX where applicable; and
- Innovation in concept, function and real-world usage.

About Cardiac Insight, Inc.

Cardiac Insight, Inc. (www.cardiacinsightinc.com) is a leading U.S. developer of advanced body-worn digital health care information systems through its proprietary software, algorithms and devices. The company’s two flagship products are its wearable ECG Sensor

and Analysis Software System, Cardea SOLO™ (www.cardeasolo.com) and Cardea 20/20 ECG™, the only 12-lead test that incorporates the International Criteria for identification of the risk of Sudden Cardiac Arrest in young athletes. Founded in 2008, Cardiac Insight is an ISO-certified company and is based in Kirkland, Washington, USA.

Cardea SOLO is a wearable, wire-free, 7-day ECG Sensor that comes complete with a PC-based, in-office Analysis Software System for the detection of adult cardiac arrhythmias, including AFib. The Cardea SOLO System leverages one of Cardiac Insight's main differentiators – its proprietary ECG Analysis Software that incorporates advanced arrhythmia detection algorithms. Cardea SOLO streamlines ambulatory patient diagnosis at the point of care, and eliminates the need for costly and time-consuming outsourced ECG scanning services.